NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDGolimumab  Gastro-intestinal system, Cytokine inhibitors, 01.05.03
REDGolimumab 50mg, 100mg Simponi®
(Injection, pre-filled pen or syringe) 		Musculoskeletal and joint diseases, Cytokine modulators, 10.01.03
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Golimumab Golimumab Gastro-Intestinal System, Chronic Bowel Disorders, Inflammatory Bowel Disease, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Golimumab Golimumab Musculoskeletal System, Arthritis, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
NICE TA220: Psoriatic arthritis - golimumab
NICE TA225: Rheumatoid arthritis - golimumab
NICE TA233: Ankylosing spondylitis - golimumab
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375:Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis